Navigation Links
Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
Date:6/3/2009

- 71% Objective Tumor Response in Combination with Docetaxel in Advanced Breast Cancer -

- 65% Objective Tumor Response in Combination with Carboplatin/Paclitaxel in Advanced Lung Cancer -

- 64% Objective Tumor Response in Combination with Carboplatin/Paclitaxel in Advanced Breast Cancer -

- Data in All Three Studies Surpassed Pre-Established Criteria for Expansion of Patient Enrollment -

- Positive Initial Data across Indications and Chemotherapy Regimens Suggests Bavituximab Could Have Broad Anti-Cancer Utility -

TUSTIN, Calif., June 3 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today highlighted the progress that the company has achieved in its Phase II program assessing the combination of bavituximab and chemotherapy in three separate cancer trials. Bavituximab is a monoclonal antibody with a unique mechanism that allows the body's own immune system to recognize and act on the tumor and its supporting blood vessels, resulting in anti-cancer effects. Bavituximab is currently being tested in combination with chemotherapy in one Phase II trial in advanced lung cancer and two Phase II trials in advanced breast cancer. Recently-reported data highlights from these studies include the following:

    -- Non-Small Cell Lung Cancer:  Bavituximab in Combination with
       Carboplatin and Paclitaxel
       In the Phase II trial evaluating bavituximab in combination with
       carboplatin and paclitaxel in non-small cell lung cancer (NSCLC)
       patients with locally advanced or metastatic disease, 11 of 17, or
       almost 65% of evaluable patients in the initial cohort of 21 patients
       achieved an objective tumor response. These early results, which
       exceeded the pre-specified endpoint needed to expand the tria
'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
2. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
3. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
4. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
5. Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV
6. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
7. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
8. Peregrine Announces Addition of The Johns Hopkins Hospital as Study Site for Bavituximab Trial in HCV Patients Co-Infected With HIV
9. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
10. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
11. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... , May 28, 2015  Service Strategies ... today announced that Fresenius Kabi, a global healthcare ... for infusion, transfusion and clinical nutrition, has achieved ... Performance (SCP) Standards for the seventh consecutive ... service effectiveness based upon a stringent set of ...
(Date:5/28/2015)... 2015 The global mannequin-based simulation ... analysis and forecast of revenue. This market was valued ... reach $1,177.8 million by 2019, at a CAGR of ... the TOC of Mannequin-Based Simulation Market for an in-depth ... of various tables and figures. http://www.micromarketmonitor.com/market-report/mannequin-based-simulation-reports-5911916854.html ...
(Date:5/28/2015)... YORK, Pa. , May 28, 2015  Unilife Corporation ... its Chairman and CEO, Alan Shortall , will present ... New York at 3:00 p.m. ET on Monday, ... be broadcast over the Internet as a "live" listen only ... archive of the event will also be available for those ...
Breaking Medicine Technology:Fresenius Kabi Recognized by Service Strategies Corp. for Technical Service Excellence 2Fresenius Kabi Recognized by Service Strategies Corp. for Technical Service Excellence 3Mannequin-Based Simulation Market Report is Expected to Reach $1,177.8 Million by 2019, at a CAGR of 19.4% from 2014 to 2019 2Mannequin-Based Simulation Market Report is Expected to Reach $1,177.8 Million by 2019, at a CAGR of 19.4% from 2014 to 2019 3
... Mylan Inc. (Nasdaq: MYL ) today ... applicable to its 6.50% Mandatory Convertible Preferred Stock (the ... of the company effective as of November 15, 2010. ... provisions of the company,s Amended and Restated Articles of ...
... Mass., Nov. 10, 2010 Hologic, Inc. (Nasdaq: ... participate in the following conferences: Rob Cascella, ... J.P. Morgan SMid Conference in New York City on ... parties are invited to listen to the live audio ...
Cached Medicine Technology:Hologic to Participate in Three Investor Conferences 2
(Date:5/28/2015)... Vancouver, BC (PRWEB) May 28, 2015 ... iData Research ( http://www.idataresearch.com ), the shoulder reconstruction ... the orthopedic small bone & joint market in ... of shoulder arthroplasty procedures in the U.S. due ... as improved device technology resulting in greater patient ...
(Date:5/28/2015)... Houston, Tx (PRWEB) May 28, 2015 ... and decision support company, announces that it will ... and pharmacogenomics (PGx) testing at the annual American ... weekend. , Next-generation sequencing evaluates the DNA in ... The DNA is analyzed for key changes or ...
(Date:5/28/2015)... Hexagon Geospatial is pleased to announce that ... spatial data and mapping services, is using Hexagon Geospatial ... for urban change assessments in Bernalillo County, New Mexico. ... Data Division implemented a countywide approach to generating pixel-resolution ... a variety of different digital aerial camera systems, BHI ...
(Date:5/28/2015)... May 28, 2015 Optimity Advisors ... implementing innovative models of care for healthcare organizations ... alternative reimbursements and help operationalize contracting and engagement ... unveils a bi-weekly series of seven “ OrangePapers” ... Based Contracting. Optimity is a strategy, operations and ...
(Date:5/28/2015)... Sacramento, PA (PRWEB) May 28, 2015 ... wishes and adventures. Each item on the ... absolutely impossible events, experiences and tasks that the owner ... is no right or wrong when it comes to ... starting a business, writing poems, publishing a book, seeing ...
Breaking Medicine News(10 mins):Health News:DePuy Synthes and Biomet Lead Fastest Growing U.S. Shoulder Reconstruction Device Market 2Health News:DePuy Synthes and Biomet Lead Fastest Growing U.S. Shoulder Reconstruction Device Market 3Health News:CompanionDx® Launches Integrated Genomic Solution at ASCO Meeting 2Health News:Hexagon Geospatial Supports Urban Change Detection Programs in New Mexico 2Health News:Hexagon Geospatial Supports Urban Change Detection Programs in New Mexico 3Health News:Optimity Advisors Now Offers Outcomes Based Contracting Services to Support Engagement Model For New Healthcare Innovative Models of Care 2
... February 22, 2011 The McKesson Foundation today ... grants as part of its Mobilizing for Healthsm initiative ... diseases through the use of mobile-phone technology. The Mobilizing ... support studies on diabetes care and management at six ...
... February 21, 2011 New research shows that ... and stroke risks may not have gotten approval from ... effects of fluid retention had been better understood. Fluid ... and strokes of medications such as Vioxx, Bextra, and ...
... using a convenient blood glucose test for diagnosing diabetes and ... Mott Children,s Hospital shows it,s not the best way to ... has become the preferred way to diagnose diabetes among the ... The simple test measures longer-term blood sugar levels -- without ...
... French . An electronic health record system ... more must be done to speed up the implementation of this ... in place effectively, doctors and front line health care workers and ... are the findings of an innovative new study assessing the effectiveness ...
... , TUESDAY, Feb. 22 (HealthDay News) -- People with ... others to develop shingles, according to a new study. ... in a painful rash with lesions. Though it was ... an increased risk for the condition, the researchers of the ...
... , TUESDAY, Feb. 22 (HealthDay News) -- Ignition devices ... the number of new arrests of drivers who were ... The team with the U.S. Centers for Disease Control ... ignition interlocks, devices that prevent someone from operating a ...
Cached Medicine News:Health News:McKesson Foundation awards $1.3 million in 6 Mobilizing for Health Research grants 2Health News:New hypothesis explains why drugs increase risk of heart attacks and strokes 2Health News:New hypothesis explains why drugs increase risk of heart attacks and strokes 3Health News:New hypothesis explains why drugs increase risk of heart attacks and strokes 4Health News:Convenient blood test not as effective for diagnosing diabetes in children 2Health News:E-health must be a priority, researchers say 2Health News:Car Ignition 'Interlocks' Thwart Alcohol-Impaired Drivers 2
Puntenney curved forceps, curved, smooth 10 mm platforms....
Nordan tying forceps, straight, titanium, 6.5 mm tying platforms....
Curved, very delicate, smooth jaws with platforms., ,Straight, very delicate, smooth jaws with platforms....
Harms-Tuebingen tying forceps, straight, 6 mm tying platforms....
Medicine Products: